BNET Industries

Market Cap:$149.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
News & Analysis
Filter by
pfizer inc. and sales strategy - All News and Analysis
J&J CEO Rubs Pfizer's Face in Disastrous Consumer Products Sale of '06
Toldya: One year ago, BNET noted that Pfizer PFE must have been crazy to sell its consumer products unit to Johnson & Johnson JNJ. The deal included brands such as Nicorette, Zantac and Benadryl. J&J's Q3 earnings report showed that the consumer products unit has done much better than its...
Merck Gives Snapshot of Combined Company: $47B in Sales; Just $7.6B in Cash
Merck MRK has produced a set of numbers giving a look at the scale of the combined company with Schering-Plough. One surprise: The new company is still just a little bit smaller than the old Pfizer PFE was. The new Merck would have had annual sales $46.7 billion, compared to...
Pfizer's Viagra Shows Signs of Flagging: Sales Down 6%
Pfizer's Viagra recorded a 6 percent sales decline, to $466 million worldwide. It wasn't just foreign currency headwinds: The decline was 14 percent in international sales and 1 percent in the U.S. Until now, Viagra has been an almost unstoppable growth machine for Pfizer. The company regularly put the price...
"Pfizer Math" Showed Lyrica Superiority Even Though Studies Never Said That, Rep Claims
Pfizer used "Pfizer Math" to persuade doctors that studies showed Lyrica was superior to two anti-seizure drugs, Neurontin and Keppra, when no comparable studies had been done -- and Lyrica was not approved to treat seizures -- according to two former pharmaceutical sales reps. by Jim Edwards
Pfizer Rep Claims Bextra Pushed on NHL's Blue Jackets
Pfizer sales reps allegedly promoted Bextra to the NHL's Columbus Blue Jackets, even though it was only approved for arthritis and menstrual pain -- and not the injuries or surgery that hockey players experience. (The Blue Jackets are an all-male team.) by Jim Edwards
Pfizer Rep Alleges Viagra Promoted With Unapproved Materials: "Get Those Things Cleaned Up!"
Blair Collins, a former Pfizer sales rep who received $2.4 million as one of the whistleblowers in the $2.3 billion Bextra settlement, alleged that reps used unapproved studies and pricing sheets to promote Viagra, among other drugs. by Jim Edwards
Pfizer's West Side Story: How "the Sharks" Sold Bextra Off-Label
Pfizer had a sales team in Florida that called themselves "the Sharks" as they promoted Bextra off-label, according to documents filed in the one of the cases that led to yesterday's $2.3 billion settlement. by Jim Edwards
Pfizer Sales Reps Discuss Having Sex With Doctors
Sales reps at Pfizer are using a CafePharma bulletin board to discuss whether it is common for their colleagues to sleep with the doctors that they are trying to persuade to write prescriptions. by Jim Edwards
Pfizer Q2: All But 3 Drugs in Decline; R&D Spend Lowest Since 2007
Sales of every single drug sold by Pfizer declined in Q2 2009 except for three: depression pill Lyrica, cancer treatment Sutent and the tiny Revatio franchise. Pfizer blamed foreign currency headwinds as it reported sales of $10.9 billion, down 9 percent; and net income of $2.3 billion, a decline of...
Novartis Q2: Generic Sales Decline Is a Warning for Pfizer, Sanofi and Abbott
Novartis' Q2 2009 results sound a warning for companies banking on a move into generics to shore up the future for their companies: Novartis' generic unit, Sandoz, performed weakly in both Q2 and the first half of the year, while its branded pharma section grew strongly. by Jim Edwards
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes

